BOTHELL, Wash and VANCOUVER, British Columbia, November 6, 2017 – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the November 2nd presentation given by Rick Stewart, Chairman and Chief Executive Officer, is now available for on-demand viewing at

Achieve provided an update and took real-time questions from investors and advisors on its clinical development plan for cytisine including recent phase 1 studies and near-term Phase 3 plans. The presentation will be available at for 90 days and investors and advisors may download shareholder materials from the “virtual trade booth” for the next three weeks.

“It was a successful and enjoyable experience to present at Virtual Investor Conferences and have the opportunity to interact with and reach more investors in a real-time, interactive setting,” said Rick Stewart.

About Achieve and Cytisine
Achieve is developing cytisine as a smoking cessation aid. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including approximately 2,000 patients in Phase 3 clinical trials conducted in Europe and New Zealand. Achieve’s focus is to address the global smoking health epidemic, which is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide. Discussions have been held with the FDA and European regulatory agencies to determine the clinical and regulatory pathway towards making cytisine widely available.

Since 2010,, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum fo